{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-102554","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.912019+00:00","generated_at":"2026-05-31T06:41:02.680199+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ProKidney refocuses Phase 3 program; discontinues PROACT 2, expects topline results Q3 2027","bullets":["Discontinues ex-U.S. PROACT 2 trial; believes PROACT 1 alone may support FDA approval under RMAT designation.","Estimated topline results from PROACT 1 by Q3 2027; expects $150-175M expense reduction.","Cash runway extended to Q1 2027; focused on U.S. market for rilparencel in advanced CKD with type 2 diabetes.","CEO cites positive REGEN-007 interim data as supporting urgency; RMAT designation granted Oct 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-102554","json":"https://secwatch.observer/filing/0000950170-24-102554.json","markdown":"https://secwatch.observer/filing/0000950170-24-102554.md","text":"https://secwatch.observer/filing/0000950170-24-102554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024102554/0000950170-24-102554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024102554/prok-20240822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:41:02.680199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}